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1  | INTRODUC TION
The processes following immunization with plasmid DNA or mRNA 
vaccines closely resemble those associated with viral infections; that 
is, within transfected cells, the encoded proteins are transcribed 
and translated and presented to the immune system. Hence, the as-
sumption that these vaccines might be especially suitable to fight 
viral infections and tumors via cell- mediated immunity was obvious. 
Indeed, early studies in animal models proved the efficacy of DNA 
vaccines in eliciting powerful cytotoxic T- cell responses.1 However, 
it was also quite early recognized that the characteristic T helper 1 
(TH1)–biased immune response alongside with production of IFN- γ 
by CD4+ and CD8+ T cells elicited by this vaccine type could be uti-
lized for modulating allergic T helper 2 (TH2) reactions, which are 
accompanied by secretion of the key cytokines IL- 4, IL- 5, and IL- 13, 
and allergen- specific IgE.
The first studies investigating the anti- allergic potential of DNA 
vaccines encoding clinically relevant allergens were performed with 
constructs encoding the major allergens from birch and house- dust 
mite. In these experiments, it was proven that in animal models im-
munization with allergen- encoding plasmid DNA itself induces a 
TH1- biased response, while concomitantly avoiding production of 
IgE and is even able to counteract an established allergic TH2 reac-
tion in a therapeutic setting.2
After a veritable hype of DNA vaccines during the 1990s, when 
the efficacy of this vaccine type against a multitude of infectious 
diseases and tumors could be demonstrated in small animals, vac-
cination experiments in primates and clinical trials turned out to 
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Abstract
Allergen- specific immunotherapy, which is performed by subcutaneous injection or 
sublingual application of allergen extracts, represents an effective treatment against 
type I allergic diseases. However, due to the long duration and adverse reactions, 
only a minority of patients decides to undergo this treatment. Alternatively, early 
prophylactic intervention in young children has been proposed to stop the increase 
in patient numbers. Plasmid DNA and mRNA vaccines encoding allergens have been 
shown to induce T helper 1 as well as T regulatory responses, which modulate or 
counteract	allergic	T	helper	2–biased	reactions.	With	regard	to	prophylactic	immuni-
zation, additional safety measurements are required. In contrast to crude extracts, 
genetic vaccines provide the allergen at high purity. Moreover, by targeting the en-
coded allergen to subcellular compartments for degradation, release of native aller-
gen can be avoided. Due to inherent safety features, mRNA vaccines could be the 
candidates of choice for preventive allergy immunizations. The subtle priming of T 
helper 1 immunity induced by this vaccine type closely resembles responses of non- 
allergic individuals and—by boosting via natural allergen exposure—could suffice for 
long- term protection from type I allergy.
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be rather sobering.3 Consequently, a variety of optimization strat-
egies was developed over the following years (Figure 1). These 
include adaptation of the sequence to mammalian codon usage 
for enhanced expression, sophisticated delivery devices including 
gene gun, Biojector 2000, and microneedles, exploration of dif-
ferent application routes (intradermal, intramuscular, intranodal), 
the	use	of	 adjuvants	 such	as	CpG	oligodeoxynucleotides	 (ODN),	
co- immunization with vectors expressing immune- enhancing or 
modulating chemokines and cytokines, and targeting of dendritic 
cells (DCs)4 or specific cellular compartments by the addition of 
certain targeting sequences.2,5-7 Based on findings, which indicate 
that genetic vaccines might be useful in priming a broad immune 
response, also prime- boost regimens combining genetic vaccines 
with protein or viral vectors have been explored.8 Furthermore, 
safety issues have been addressed by promoting the “revival” of 
mRNA vaccines9 and introducing self- replicating (and thereby self- 
limiting) DNA and mRNA vaccines based on alphaviral sequences.10
This review discusses the current status of DNA- and mRNA- 
based vaccines against type I allergic reactions and provides an 
overview of recent and most promising concepts tested in the 
clinics.
2  | E ARLY APPROACHES
The first studies investigating the anti- allergic effects of DNA im-
munization used simple conventional plasmids driving expression 
by a CMV promoter. Intramuscular immunization of rats with plas-
mid DNA encoding the house- dust mite allergen Der p 5–induced 
specific immune responses, but prevented the formation of Der p 
F IGURE  1 Optimization strategies for genetic vaccines. Modifications of the genetic sequence encoding the antigen of interest 
include	(A)	recoding	in	order	to	adapt	the	codon	usage,	adjust	the	GC	content,	and	remove	sequences	that	inhibit	efficient	translation	(B)	
optimization	of	5′	and	3′	UTRs	to	enhance	mRNA	stability	and	translation	(C)	usage	of	targeting	sequences	that	shuttle	the	translated	
protein into specific cellular compartments (D) use of self- replicating RNAs by incorporating alphavirus replicases and (E) mutations of the 
antigen	itself	to	influence	its	immunogenicity	and/or	allergenicity.	Such	optimized	sequences	can	be	used	directly	as	mRNA	vaccines,	or	
expressed from a plasmid DNA vector (pDNA). By choosing different promoters, expression strength and cell specificity can be adjusted. 
Using minicircle plasmids, unwanted bacterial sequences or antibiotic resistance genes needed for production can be removed from 
the	plasmid	backbone.	Immunostimulatory	CpG-	ODN	can	be	covalently	linked	to	an	antigen	of	interest	or	incorporated	in	liposomal	
formulations	or	viruslike	particles	(VLP)	to	enhance	their	efficacy.	Genetic	vaccines	can	be	injected	intramuscularly	(i.m.),	intradermally	(i.d.,	
also using injection devices like the Biojector™ 2000) or even applied intranodal. Alternatively, (epi)cutaneous vaccination can be achieved 
with biolistic devices (gene gun) or using microneedles, with or without additional in vivo electroporation
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5–specific IgE. Moreover, pre- vaccination with this construct pre-
vented histamine release in bronchoalveolar lavage fluids and airway 
hyperresponsiveness upon challenge with aerosolized allergen. This 
effect was long- lasting and transferable by CD8+ T cells from im-
munized to naïve animals.11	Subsequently,	plasmid	DNA	constructs	
encoding a multitude of model allergens and clinically relevant mol-
ecules have been used for anti- allergic immunization of rodents (re-
viewed in2).
Several	 of	 these	 early	 studies	 in	 mice	 have	 demonstrated	 a	
clear correlation between IFN- γ secretion by T cells and production 
of	 IgG2a	 and	protection	 from	 type	 I	 allergy	 by	 plasmid	DNA	vac-
cines.11-14 Moreover, we could show that, in contrast to wild- type an-
imals, IFN- γ, but not IL- 12p40–knockout mice failed to be protected 
from allergic sensitization by immunization with plasmids encoding 
grass pollen allergen.15 These findings underscore the central role of 
this cytokine in prevention of type I allergy.
3  | INDUC TION OF BLOCKING IGG BY 
GENETIC VACCINATION
In rodents, antibody responses following immunization with genetic 
vaccines	encoding	allergens	are	dominated	by	 the	 IgG2a	 subclass,	
which notably is able to activate complement. This clearly contrasts 
the	situation	in	humans	after	SIT	or	SLIT,	which	mainly	induce	IgG4	
antibodies lacking the capacity to fix complement. Allergen- specific 
IgG2a	antibodies	can	subsequently	be	boosted	by	exposure	to	the	
respective allergen as during sensitization or provocation via the air-
ways. Furthermore, we could demonstrate that once induced, this 
humoral response type is long- lasting and can be maintained even 
after repeated challenges with aerosolized allergen.16	With	regard	to	
IgG	responses	induced	against	allergens,	the	term	“protective”	con-
forms to the potential to block allergen- IgE interactions. Activation 
of basophils from mice immunized with a DNA vaccine encoding 
Bet v 1 was shown to be increased following incubation with the 
allergen in the absence of antibody- containing plasma, indicative of 
the	presence	of	blocking	 IgG.17 To increase antibody responses in 
general and to generate blocking antibodies, it has been proposed 
that—besides efficient leader sequences in the plasmid constructs 
for secretion of allergen—techniques such as in vivo electroporation 
should be employed.18 In vivo electroporation following intramuscu-
lar DNA immunization against Der p 2 led to a substantial increase 
in	IgG	production,	whereas	the	amount	of	IFN-	γ produced remained 
unaffected. However, it remains to be elucidated whether this im-
proved humoral response contributes to the observed protective 
effect.19 In contrast to rodents, humans in general mount weak (an-
tibody) responses after standard injection of genetic vaccines, most 
likely due to inefficient cellular uptake. Hence, methods to facilitate 
in vivo delivery of genetic vaccines have been employed, including 
gene gun vaccination, which induced protective antibody responses 
against hepatitis B in human non- responders to conventional im-
munization.20 Currently, a clinical study investigating the immuno-
genicity of a DNA vaccine against hepatitis B combined with in vivo 
electroporation in subjects with chronic infection is underway (clini-
caltrials.gov identifier: NCT02431312).
4  | TAILOR- MADE GENETIC VACCINES
Vaccination with plasmid DNA has been performed in many clini-
cal studies without proven serious adverse events. However, gen-
eral apprehensions about the safety of this vaccine type have been 
raised. These comprise (a) integration of the vaccine itself into the 
genome, which could lead to cancer development; (b) long- term 
persistence of the administered plasmid DNA, potentially triggering 
production of anti- DNA antibodies and thus leading to autoimmun-
ity; and (c) long- term expression of the encoded antigen, thereby 
causing systemic immunological effects such as a generalized in-
flammatory	milieu.	As	a	consequence,	the	FDA	in	the	United	States	
and	 the	Paul	 Ehrlich	 Institute	 in	Germany	 have	 categorized	 vacci-
nation with plasmid DNA as gene therapy.21 Also allergy- specific 
concerns have been raised; primarily that uncontrolled expression 
of natural allergens could potentially cause adverse events by cross- 
linking of preexisting IgE. To avoid the before- mentioned problems, 
safety- optimized genetic vaccines have been established (Figure 1).
Detailed knowledge about structural features of major allergens 
including their immunodominant B- and T- cell epitopes enables 
the generation of DNA vaccines encoding so- called hypoallergenic 
molecules, which no longer bind specific antibodies, but retain their 
T- cell epitopes. In this case, side effects associated with binding of 
IgE to native allergen can be avoided during therapy, while enabling 
efficient recruitment of allergen- specific TH1 cells. Approaches to 
meet these requirements include fragmentation of allergen,22 intro-
duction of point mutations,22 and the use of epitope vaccines encod-
ing known CD4+ and/or CD8+ T- cell epitopes.23-24	Whereas	DNA	
vaccines encoding two hypoallergenic fragments or a hypoallergenic 
mutant of the birch pollen allergen Bet v 1 both protected mice from 
sensitization with the allergen, only the fragment vaccine was able 
to reverse an established Th2- type response. Notably, the fragment 
vaccine did not induce Bet v 1–specific antibodies indicative of dif-
ferences in the three- dimensional structure of the encoded frag-
ments and the wild- type allergen.22	With	 regard	 to	DNA	vaccines	
encoding	epitopes,	results	are	contradictory:	While	in	some	studies	
increased	levels	of	IgG2a	and	IFN-	γ together with suppression of IgE 
upon sensitization was noted,24 in other cases these vaccines could 
not convincingly demonstrate their anti- allergic potential.23
Alternatively, genetic vaccines, which also avoid release of large 
amounts of native allergen, can be created by the addition of cer-
tain targeting sequences to the encoded allergen. One possibility is 
targeting the allergen for proteasomal degradation by forced ubiq-
uitination.25 The generated peptides are then either presented on 
MHC- I, thereby facilitating the induction of CD8+ T cells (which 
have been shown to counteract allergic responses as producers of 
IFN- γ) or directly get loaded onto MHC- II molecules by a process 
termed autophagy. Alternatively, the encoded allergen can be tar-
geted to the endolysosomal compartment by the addition of LIMP 
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(lysosome membrane protein) or LAMP (lysosomal- associated mem-
brane protein) sequences. The resulting peptides are subsequently 
loaded onto MHC- II molecules. Both approaches have in common 
that no native allergen is secreted, which could cross- link preexisting 
IgE.
With	 regard	 to	 preventive	 immunization	 of	 healthy,	 young	 in-
dividuals against allergic sensitization, safety measurements have 
to be even stricter. However, using mRNA vaccines, the required 
safety profile could potentially be warranted. This vaccine type uti-
lizes minimal vectors, which basically consist of the gene of inter-
est,	 a	 poly-	adenosine	 tail	 of	more	 than	 30	 residues	 at	 the	 3′	 end	
and	a	7-	methylguanosine	cap	structure	at	the	5′	end.	Additionally,	
untranslated	regions	 (UTR)	at	 the	3′	and/or	5′	end	have	been	em-
ployed to enhance mRNA stability and thus increase protein transla-
tion. mRNA vaccines cannot integrate into the host genome and are 
readily cleared from the organism by RNAses. Furthermore, there 
has been no single report on formation of antibodies against mRNA 
molecules linked to autoimmune diseases. In 1990, naked mRNA 
was injected into muscle of mice and found to result in expression 
of different reporter molecules.26 Administration of a liposome- 
formulated mRNA vaccine encoding the influenza virus nucleopro-
tein into mice induced virus- specific cytotoxic T- cell responses.27 
Unexpectedly, also unprotected mRNA was found to elicit powerful 
humoral and cellular immune responses.28 Owing to this and their 
unsurpassed inherent safety features, this type of genetic vaccine 
has been repeatedly employed in clinical trials mainly in the cancer 
field.	So	far,	immunotherapy	with	mRNA	has	been	performed	in	pa-
tients suffering from melanoma, non- small- cell lung cancer, renal 
cell carcinoma, and prostate cancer.21,29-30 Recently, a protective 
mRNA vaccine against rabies was successfully tested in healthy 
subjects.31 Based on a study demonstrating that immunization with 
mRNA preferentially induces a TH2- biased T- helper cell polarization, 
which could only be redirected toward an anti- allergic TH1 response 
by the addition of adjuvants,32 it was initially supposed that mRNA 
would not be suitable for counteracting allergic reactions. However, 
in the meantime mRNA vaccines have proven to be equally potent 
inducers of TH1 responses without adjuvantation compared to their 
DNA counterparts.33,34 Notably, the immunogenicity of allergen- 
encoding mRNA appeared to be reduced compared to DNA, at 
least for the grass pollen allergen Phl p 5. However, obviously even 
weak TH1 priming was sufficient for expansion of protective TH1 
cells upon exposure to the specific allergen as mice were protected 
from formation of specific IgE.34 This process resembles the recall 
responses observed in vaccinated individuals after contact with in-
fectious agents. In individuals vaccinated against allergen(s), subtle 
TH1 priming and recruitment of TH1 cells could provide long- term 
protection as boosting of this immunity would naturally occur via 
exposure to allergen such as during the pollen season. Indeed, we 
could demonstrate sustained alleviation of airway hyperresponsive-
ness and reduction in lung eosinophilia under repeated exposure to 
aerosolized allergen.16
Besides targeting subcellular compartments, efforts have been 
made to generate DNA vaccines that express proteins targeted to 
DCs with the aim to enhance specific immune responses (reviewed 
in35).	With	 respect	 to	 allergy	DNA	 vaccines,	 recent	 studies	 found	
that targeting an allergen to DCs by encoding DEC- 205 fusion pro-
teins alleviates allergic asthma in mice.36,37 Interestingly, although 
non- targeted allergen also protected from sensitization37, the latter 
was associated with a TH1 phenotype, while DC targeted vaccina-
tion induced reduced levels of IFN- γ production36,37 but was asso-
ciated with elevated numbers of CD4 + CD25 + FoxP3 + T cells37. 
Surprisingly,	both	TH-	1	as	well	as	 regulatory	T-	cell	 induction	were	
equally efficient in suppressing allergic lung inflammation, highlight-
ing that multiple mechanisms can confer allergy protective immune 
responses after DNA immunization.
5  | MIMICKING THE HE ALTHY STATUS
Since	the	discovery	of	 IL-	10-	producing	T	regulatory	1	 (Tr1)	cells,	
also in the field of allergen- specific immunotherapy, the main 
focus was set on this immune cell type, whereas immune modula-
tion toward TH- 1 responses has been seen more and more critical. 
With	regard	to	the	TH-	1-	promoting	potential	of	genetic	vaccines,	
concerns have been raised that this response type could lead to 
exaggerated inflammation, in particular of the airways, and even 
autoimmunity. However, we and others found no pathological 
inflammation following genetic immunization, pointing to a self- 
limiting capacity of TH- 1 cells via autologous IL- 10 secretion.38 
Even after repeated monthly exposure to aerosolized allergen, an 
initially set protective TH- 1 bias did not end up in pathological TH- 
1- mediated inflammation.16 Alongside with the above- mentioned 
importance of modulating the allergen- driven TH- 2 response to-
ward TH- 1, we and others also observed induction of regulatory T 
cells following immunization with plasmid DNA.17,39 Likewise, pro-
tection did not necessarily correlate with total levels of IFN- γ17, 
suggesting that besides IFN- γ production other mechanisms might 
play a role in protection from allergic responses after plasmid- 
based immunization.
According to the hygiene hypothesis, exposure to a traditional 
farming environment, that is, contact with farm animals and hay as 
well as consumption of non- pasteurized milk early in life, protects 
from development of allergies.40	 Specifically,	 children	 exposed	 to	
such a diversity of microbial compounds have lower frequencies of 
asthma, hay fever, and atopic sensitization.41 Furthermore, the pro-
tective “farming effect” also leads to a reduced risk for atopic sensiti-
zation in adulthood.42 Obviously, certain microbial products provide 
a strong activating stimulus for the innate immune system leading to 
an immune status counteracting allergic reactions.41 To investigate 
the mechanisms underlying the “farming effect” mice bred in a cattle 
barn or a conventional animal facility were sensitized with allergens 
via the skin and the resulting immune responses were analyzed.43 
Compared to the conventionally raised animals, the farm mice de-
veloped an elevated number of activated CD4+ T cells early in life. 
Their cytokine profile was skewed toward IL- 17 and IL- 22 accompa-
nied by increased IL- 10 secretion. It was concluded that the farming 
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environment provides a strong, allergy protective IL- 22 stimulus, 
which might also provide protection from contact skin allergy.
To elaborate how the immune system of healthy, non- allergic in-
dividuals deals with allergens, we studied a large cohort of donors 
and—in line with a recently postulated concept44—found that non- 
allergic subjects do not display immunological ignorance, but react 
by mounting “healthy” immune reactions.45 These have been shown 
to be associated with regulation of epithelial barrier function46 as 
well as T- cell responses.47-48	When	we	expanded	allergen-	specific	
T memory cells from peripheral blood mononuclear cells, we de-
tected a broad spectrum of TH response types, which counteract 
allergic reactions. In a small percentage of subjects, we even found 
allergen- specific Th17/TH22 responses presumably contributing 
to regulation of TH2 responses. Moreover, we could demonstrate 
that the prevalence of certain response types depends on the living 
environment by comparing responses of healthy individuals with a 
traditional farming background to those of townspeople. Notably, 
allergen- specific T cells from townspeople displayed an even more 
pronounced tendency toward pro- inflammatory responses. Based 
on our data, variable and complex immune deviation mainly toward 
a pro- inflammatory phenotype can be assumed to confer natural 
protection from allergy.44	Genetic	 vaccines—and	especially	mRNA	
vaccines—might have the potential to deliver exactly this naturally 
occurring immunity.
6  | PROPHYL A XIS VS THER APY
In therapeutic animal models of allergy, genetic vaccines have proven 
their efficacy in counteracting TH2 responses by suppression of 
IgG1,	IgE	and	allergic	lung	inflammation	and	by	induction	of	IFN-	γ, 
and	 IgG2a.	However,	 to	modulate	 or	 even	 convert	 an	 established	
immune response is way more difficult than directing the develop-
ing immune system toward the desired protective pathways. Hence, 
repeated administration of high doses of the respective vaccine is 
required for only moderate downregulation of allergic symptoms.7 
On the contrary, in mice suboptimal vaccine doses, which even fail to 
induce measurable immune responses, have been shown to lead to 
anti- allergic reactions following provocation with allergen.19,34 Also 
in humans barely detectable immune responses, as elicited by vac-
cination with mRNA vaccines, might be sufficient for maintenance 
of lifelong protection from allergy without booster immunizations. 
After the initial immunological bias is set, this is guaranteed due 
to natural exposure to the respective allergen(s).6 Clearly, testing 
prophylactic allergy vaccinations in the clinics would require care-
ful selection of young children with a highly predictable risk to de-
velop type I allergy. Besides adducing family anamnesis, diagnosis of 
certain food allergies during the first years of life,49 and of allergic 
reactions to so- called primary sensitizers,50 identification of suscep-
tibility genes for allergy and asthma51 provides a basis for delimita-
tion of candidate individuals.
Whereas	 genetic	 vaccines	 for	 allergy	 prevention	 most	 likely	
would act by inducing pro- inflammatory immune reactions, 
preventive treatment of children by oral or sublingual administration 
of allergen(s) was already performed with the aim to induce regula-
tory	 responses.	 Sublingual	 administration	 of	 a	mixture	 of	 allergen	
extracts from house- dust mite, cat, and timothy grass to high- risk 
children at an age of 12- 30 months failed to induce regulatory T 
cells against the allergens delivered via the mucosa.52 The authors 
speculated that instead of promoting tolerance, the intervention did 
not trigger immunologic processes at all or only worked as a weak 
booster. As infants are not capable of holding the allergen drops 
under the tongue for up to 3 minutes, the allergen concentration 
at the mucosal surface might have been too low and the exposure 
time too short for tolerogenic mucosal DCs to acquire enough al-
lergen. Oral administration of house- dust mite extract in high- risk 
children below 1 year of age lacking skin test reactivity to common 
allergens resulted in reduced sensitization to any common allergen, 
but not to house- dust mite.53 In contrast, 2- to 5- year- old children 
sensitized against house- dust mite and/or grass pollen treated by 
sublingual immunotherapy with the respective extract showed an 
upregulation	of	specific	IgG	and	IL-	10-	associated	function	of	regula-
tory T cells in vitro, whereas specific IgE and skin prick test reactivity 
remained comparable to the placebo group.54 These data indicate 
that induction of allergen- specific regulatory T- cell responses suf-
ficient to prevent allergic sensitization is a difficult task and that 
additional “pro- inflammatory” approaches including genetic vacci-
nation	and	the	use	of	 immunomodulators	such	as	CpG	should	also	
be taken into consideration. Notably, for prevention of allergies tim-
ing of intervention seems to be crucial: High- risk infants between 
4 and 11 months of age consuming at least 6 g of peanut protein 
per week until 60 months displayed a significantly reduced rate of 
peanut allergy compared to those avoiding peanuts.55 It has been 
suggested that using defined recombinant allergens or derivatives 
thereof combined with optimized dosage and timing for oral toler-
ance induction in children could provide a powerful measurement in 
allergy prevention.56
7  | CURRENT CLINIC AL DE VELOPMENTS
The company Immunomic Therapeutics recently developed a DNA 
vaccine by incorporating the sequence of lysosomal- associated 
membrane protein 1 (LAMP- 1) into plasmids encoding the major 
allergens	Cry	 j	 1	or	Cry	 j	 2	 from	Japanese	 red	 cedar	 (JRC)	pollen.	
Immunization of BALB/c mice with these constructs resulted in 
TH1- biased immune responses as indicated by high levels of IFN- γ 
and	anti-	Cry	 j	1	or	anti-	Cry	 j	2	 IgG2a	antibodies	and	 low	 levels	of	
IgE. Adoptive transfer of T cells from immunized into naïve mice fol-
lowed by Cry j 1/Cry j 2 protein boosts revealed that CD4+ T cells 
are the immunological effectors of DNA immunization in this allergy 
model.57 Based on these data, a series of clinical trials was initi-
ated	 (Table	1).	 Individuals	 sensitized	 to	 Japanese	 red	 cedar	 and/or	
mountain cedar were immunized four times at 14- day intervals with 
2 or 4 mg, respectively, of the plasmid encoding Cry j 2 linked to 
LAMP-	1	(JRC-	LAMP-	Vax).	Immunizations	were	well	tolerated	by	all	
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participants. Interestingly, 130 days after the 4th immunization 10 
of	12	patients	sensitized	to	Japanese	red	cedar	and	six	of	11	patients	
sensitized to mountain cedar displayed a conversion of skin test from 
positive to negative.58 However, as skin prick tests at the time- point 
of enrollment and at the study end- point were performed using al-
lergen extracts, it is difficult to assess whether treatment induced 
any Cry j 2- specific immunological effects. Notably, three of three 
subjects tested positive for Cry j 2 at screening were found to be 
skin test negative for Cry j 2 on day 132.
Approximately 300 days after the first vaccination, some of the 
study participants received one booster dose of 2 mg to assess long- 
term safety and recall immune responses. Interestingly, a substan-
tial number of prick test conversions from positive to negative were 
also noted for unrelated allergens pointing to a possible bystander 
suppressive effect provided by T helper cells.59	 Specific	 IgE	 titers	
remained unchanged upon immunization with the Cry j 2- LAMP 
vaccine and unlike in the preceding mouse study, only a marginal 
increase	in	specific	IgG	was	noted.58
As an alternative to intramuscular injections, in a follow- up study 
this vaccine was also delivered intradermally using the Biojector™ 
2000 device (clinicaltrials.gov identifier: NCT02146781). In an ongo-
ing phase I trial (clinicaltrials.gov identifier: NCT02851277), a multi-
valent peanut- LAMP- 1 DNA vaccine including Ara h 1, Ara h 2, and 
Ara h 3 is evaluated in peanut allergic patients by intradermal (undis-
closed “low or high” dose) or intramuscular injections (undisclosed 
“high” dose; Table 1).
The LAMP- Vax platform utilizes an up- to- date targeting ap-
proach, which should avoid therapy- induced side effects caused 
by high amounts of free allergen. Alternatively, the synthesized 
allergen- LAMP fusion protein is directly shuttled into the lysosomal 
compartment, circumventing exposure of the patient to native aller-
gen. Instead of aiming to induce tolerance, this therapy is designed 
to	reverse	the	allergenic	IgE/TH2	response	toward	an	IgG/TH1	re-
sponse (https://www.immunomix.com/technology/allergy/).
Another	approach,	which	utilizes	non-	methylated	CG-	rich	DNA	
sequences	 (CpG-	motifs)	 either	 as	 adjuvant	 or	 even	 as	 unspecific	
treatment, has already proven its suitability in allergen- specific im-
munotherapy. These sequences are common in bacteria, but are 
mostly	methylated	in	the	genome	of	vertebrates.	CpGs	bind	to	Toll-	
like receptor 9 (TLR9) located in the endosomes of plasmacytoid 
DCs and monocyte- derived DCs (mDCs) in mice, but only of plas-
macytoid DCs in humans as well as of B cells.60 TLR9 signaling has 
been shown to promote TH- 1 immune responses in mice61 and hu-
mans62;	hence,	CpGs	appear	attractive	for	use	as	adjuvants	in	spe-
cific allergen immunotherapy. Due to differences in their structure, 
type	A	and	B	CpGs	exert	distinct	 immunological	activities:	A-	type	
CpGs	contain	their	motifs	in	a	palindromic	form	and	their	backbone	
consists of phosphodiester bonds, whereas the backbone of B- type 
CpGs	is	chemically	stabilized	by	phosphorothioate	bonds	and	they	
do	not	form	palindromes.	Whereas	A-	type	CpGs	have	been	identi-
fied	as	producers	of	type	I	interferons,	B-	type	CpGs	essentially	in-
duce IL- 12 secretion.
Most	 early	 studies	 in	 mice	 have	 shown	 that	 CpGs	 can	 pro-
tect from allergic asthma by increasing levels of IFN- γ and IL- 12 
resulting in suppression of IL- 5 and concomitant lung eosino-
philia.63 More recent data revealed that this reduction in lung in-
flammation is also accompanied by an upregulation of IL- 10 and 
CD4	+	Foxp3	+	T	 cells	 in	 the	 lung,	 indicating	 that	 CpG-	induced	
suppression of allergic inflammation may also contain a regula-
tory component.64 Already in 2006, ragweed allergen Amb a 1 
TABLE  1 Clinical trials using the LAMP- Vax platform against type I allergies
Vaccine
Allergen 
(source) Regimen
Method/
Route Dose Phase Identifier No Reference
CryJ2-	LAMP	DNA Cry j 2 
(Japanese	red	
cedar)
4 × 14- d intervals i.m. injection 2 mg or 4 mg Ia NCT01707069 58
CryJ2-	LAMP	DNA Cry j 2 
(Japanese	red	
cedar)
1× (continuing Ia) i.m. injection 2 mg Ib NCT01966224 58
CryJ2-	LAMP	DNA Cry j 2 
(Japanese	red	
cedar)
4 × 14- d intervals i.d. Biojector 
2000
1.08 mg or 
2.16 mg
Ic NCT02146781
ASP4070a Cry j 2 
(Japanese	red	
cedar)
1× or 4× i.d. or i.m. “high or low” I NCT02469688
ASP4070a Cry j 2 
(Japanese	red	
cedar)
14- d intervals i.d. “high or low” II NCT03101267
ASP0892b Ara h 1, 2, 3 
(peanut)
4 × 14- d intervals i.d. or i.m. “high or low” I NCT02851277
i.m., intramuscular; i.d, intradermal.
aAlso	known	as	JRC	(Japanese	red	cedar)-	LAMP-	Vax.	
bAlso known as ARA- LAMP- Vax. 
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covalently	coupled	to	type	B	CpG-	ODNs	was	employed	for	treat-
ment of ragweed allergic patients, who received six injections at 
weekly intervals (Table 2). Treatment was well tolerated and no se-
vere side effects occurred.65 This could be explained by a reduced 
IgE reactivity of the coupled Amb a 1 as shown by histamine release 
from human basophils.61	 Whereas	 vascular	 permeability	 deter-
mined via measurement of serum albumin concentrations in nasal 
lavages remained unaffected, symptom and quality- of- life scores 
were improved during the first and also the second pollen season 
after therapy. Interestingly, the treated patients did not mount an 
increase in IgE titers as usually observed shortly after the pollen 
season. However, a follow- up phase II clinical study had to be ter-
minated due to very mild symptoms of the placebo control group 
in the relevant pollen season, making measurement of a treatment 
effect impossible (clinicaltrials.gov identifier: NCT00387738). In 
humans,	 the	 type	B	CpG-	ODN	used	 in	 these	 studies	 are	 potent	
stimulators of B cells and promote maturation and activation of 
plasmacytoid DCs, but induce only small amounts of IFN- α/β. 
Furthermore,	in	contrast	to	mice,	where	type	B	CpGs	induce	IL-	12	
production by mDCs, human mDCs do not express TLR9. Hence, 
inefficient	stimulation	of	human	DCs	by	B-	type	CpGs	might	pro-
vide an explanation for the observed low clinical efficacy of the 
Amb	a	1-	CpG	conjugates.
With	the	aim	to	stabilize	and	protect	A-	type	CpG-	ODN	from	di-
gestion by DNAse I, they were encapsulated into viruslike particles 
(VLP) derived from bacteriophage Qβ.	 The	 CpG	 containing	 VLPs,	
termed QβG10,	were	then	mixed	with	house-	dust	mite	extract,	and	
this formulation was tested in phase I/IIa clinical trial with house- 
dust mite allergic patients. Therapy was started with extract only 
administered subcutaneously at a standard dose- escalating cluster 
regimen, that is, increasing doses at 30- minutes intervals in two 
sessions	with	1	week	in	between.	Subsequently,	treatment	with	the	
extract mixed with QβG10	was	performed	 six	 times	 at	weekly	 in-
tervals.66 Conjunctival provocation tests revealed almost complete 
tolerance. The treatment significantly reduced rhinitis and asthma 
symptoms and this improvement lasted at least until 38 weeks after 
finishing the therapy. Injections of QβG10	 and	 house-	dust	 mite	
extract	 induced	an	increase	in	allergen-	specific	 IgG	and	in	IgE,	the	
latter being only transient.
A follow- up study was performed in which additional groups 
of patients were treated with house- dust mite extract alone or 
QβG10	alone.67	Surprisingly,	clinical	effects	observed	in	the	QβG10	
group were comparable to that of the QβG10	plus	extract	group.	
Encouraged by these results, a phase IIb trial was accomplished in 
a large cohort of patients receiving QβG10	at	a	high	or	a	low	dose,	
respectively, without allergen.68	Significant	improvement	of	com-
bined symptom and medication scores were monitored in the high- 
dose group compared to placebo. In conjunctival provocation tests 
a 10- fold increase in allergen tolerance was observed. How this un-
specific allergy treatment is able to ameliorate allergic symptoms is 
not	entirely	understood.	With	a	size	of	30	nm,	the	VLPs	get	readily	
transported to draining lymph nodes,69 where they are phagocyto-
sed	and	their	CpG	content	can	directly	be	delivered	to	the	endo-
lysosomes of plasmacytoid DCs.70	Upon	binding	of	CpGs	to	TLR9,	
TH- 1- promoting and simultaneously TH- 2- suppressing cytokines 
are produced.71	In	mice,	it	has	been	shown	that	CpG	can	ameliorate	
the asthmatic airway response by upregulating the activity of IDO 
(indoleamine 2,3 dioxygenase) in DCs leading to suppression of T 
cells.72	A	direct	effect	of	CpG-	ODN	alone	also	perfectly	fits	to	the	
hygiene hypothesis as stimulation of innate immunity by bacterial 
products is known to counteract allergic reactions. This is in line 
with our findings that healthy farmers show a tendency to mount 
allergen- specific regulatory responses, whereas townspeople 
preferentially develop inflammatory reactions.45	 However,	 CpGs	
could also directly act on mast cells as these also express TLR9.73
Undergoing controlled glucocorticosteroid withdrawal, patients 
with mild- to- moderate persistent allergic asthma were treated with 
the same accumulating dose of QβG10	 in	 another	 clinical	 study.	
Significant	 improvement	 of	 all	 patient-	reported	 parameters	 and	 a	
significantly higher forced expiratory volume compared to placebo 
was recorded.74 However, when patients were treated in a further 
study with this compound, no significant differences between verum 
and placebo could be detected.75 In this case, QβG10	turned	out	to	
be ineffective in patients with uncontrolled moderate- to- severe 
TABLE  2 Clinical	trials	with	CpG-	ODN	against	type	I	allergies
Vaccine Allergen (source) Regimen Method/Route Dose Phase Identifier No Reference
AIC (TOLAMBA™) Amb a 1 (ragweed) 6 × 1- wk intervals s.c. injection escalating 
(3- 30 μg)
II NCT00537355 65
AIC (TOLAMBA™) Amb a 1 (ragweed) 6 × 1- wk intervals s.c. injection escalating (“dose 
intense/low 
dose”)
II NCT00387738
QβG10	+	HDM Extract (HDM) 6 × 1- wk intervals s.c. injection 300 μg I/IIa NCT00652223 66
QβG10 No allergen 6 × 1- wk intervals s.c. injection 500 or 1000 μg IIb NCT00800332 68
QβG10 No allergen 7 × 1- wk intervals s.c. injection 900 μg IIa NCT00890734 74
QβG10 No allergen 7 × 1- 2- wk intervals s.c. injection 300, 1000, or 
2000 μg
IIb NCT01673672 75
AIC,	Amb	a	1	conjugated	to	CpG-	B	DNA;	HDM,	house-	dust	mite;	s.c.,	subcutaneous;	ODN,	oligodeoxynucleotides;	QβG10,	CpG-	A	ODN	encapsulated	
in Qβ viruslike particle.
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allergic asthma as add- on therapy to inhaled corticosteroids plus 
long- acting beta- agonists.
8  | CONCLUSIONS
Unspecific	treatment	as	with	CpG	DNA	lacking	any	allergen	prepa-
ration or extract would provide the opportunity to treat different 
allergies with a single compound. Besides the failure to demonstrate 
therapeutic efficacy of this approach in certain groups of patients, 
it has to be kept in mind that such an allergen- free treatment might 
only work for allergies against ubiquitous and perennial allergens like 
those derived from house- dust mite. In this case, permanent contact 
with allergen(s) might contribute to the therapeutic effect.
Theoretically, targeting of the encoded allergen to the ly-
sosomal compartment as provided by the LAMP- Vax platform 
should prevent release of native allergen into the circulation, 
avoiding therapy- induced side effects. By addressing the endoso-
mal/lysosomal compartment, enhanced MHC- II presentation and 
the induction of powerful CD4+ T- cell responses are induced. The 
low number of immunizations leading to reversion of skin tests 
appears promising. It has to be clarified in ongoing and future 
clinical trials whether the barely detectable increase in allergen- 
specific	 IgG	titers	 following	 this	 intervention	can	be	boosted	by	
natural exposure of vaccinated subjects to the respective (pollen) 
allergen.
Whereas	the	recently	or	currently	evaluated	DNA-	based	vac-
cines in the clinics are designed for therapeutic interventions, 
potentially the greatest strength of this vaccine type would be 
proven by prophylactic vaccination of healthy young individuals. 
However, the safety and efficacy of genetic vaccines encoding 
allergens will have to be demonstrated in healthy as well as sen-
sitized adults beforehand. Clinical trials investigating these issues 
have been performed or are currently underway. Highly probable, 
prophylactic as well as therapeutic genetic vaccines of choice will 
have to be rendered hypoallergenic; that is, no native allergen is 
secreted, thereby avoiding de novo IgE production (preventive 
immunization) or cross- linking of pre- formed IgE (therapeutic im-
munization). Moreover, candidate vaccines will most likely be de-
signed to target certain types of immune cells. This can be either 
CD4+ T cells, which are most potent in preventing or modulating 
allergic TH2 responses or DCs, known for their ability to modu-
late and regulate immune responses. The former can be achieved 
by transporting the expressed allergen into subcellular compart-
ments via addition of targeting sequences, the latter by formu-
lations addressing specific receptors on DCs. Finally, due to their 
inherent safety features, mRNA vaccines could represent the ideal 
candidates to fulfill the requirements for prophylactic immuniza-
tion against type I allergies.
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